These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 30689922)

  • 1. Prognostic Characterization of Higher-Grade Meningiomas: A Histopathological Score to Predict Progression and Outcome.
    Bertero L; Dalla Dea G; Osella-Abate S; Botta C; Castellano I; Morra I; Pollo B; Calatozzolo C; Patriarca S; Mantovani C; Rudà R; Tardivo V; Zenga F; Garbossa D; Papotti M; Soffietti R; Ricardi U; Cassoni P
    J Neuropathol Exp Neurol; 2019 Mar; 78(3):248-256. PubMed ID: 30689922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. TERT promoter mutation is associated with worse prognosis in WHO grade II and III meningiomas.
    Biczok A; Kraus T; Suchorska B; Terpolilli NA; Thorsteinsdottir J; Giese A; Tonn JC; Schichor C
    J Neurooncol; 2018 Sep; 139(3):671-678. PubMed ID: 29808339
    [TBL] [Abstract][Full Text] [Related]  

  • 3. World Health Organization Grade II Meningiomas: The Role of Adjuvant/Salvage Gamma Knife Surgery After Initial Surgery and Prognostic Factor Assessment.
    Liu X; Shan B; Wang M; Xu J
    World Neurosurg; 2018 Jan; 109():e352-e362. PubMed ID: 28987849
    [TBL] [Abstract][Full Text] [Related]  

  • 4. WHO grade II and III meningiomas: a study of prognostic factors.
    Durand A; Labrousse F; Jouvet A; Bauchet L; Kalamaridès M; Menei P; Deruty R; Moreau JJ; Fèvre-Montange M; Guyotat J
    J Neurooncol; 2009 Dec; 95(3):367-375. PubMed ID: 19562258
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Microscopic brain invasion in meningiomas previously classified as WHO grade I is not associated with patient outcome.
    Biczok A; Jungk C; Egensperger R; von Deimling A; Suchorska B; Tonn JC; Herold-Mende C; Schichor C
    J Neurooncol; 2019 Dec; 145(3):469-477. PubMed ID: 31713016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic value of estrogen receptor in WHO Grade III meningioma: a long-term follow-up study from a single institution.
    Hua L; Zhu H; Li J; Tang H; Kuang D; Wang Y; Tang F; Chen X; Zhou L; Xie Q; Gong Y
    J Neurosurg; 2018 Jun; 128(6):1698-1706. PubMed ID: 28820306
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The Simpson grading revisited: aggressive surgery and its place in modern meningioma management.
    Gousias K; Schramm J; Simon M
    J Neurosurg; 2016 Sep; 125(3):551-60. PubMed ID: 26824369
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Necrosis is a consistent factor to recurrence of meningiomas: should it be a stand-alone grading criterion for grade II meningioma?
    Góes P; Santos BFO; Suzuki FS; Salles D; Stávale JN; Cavalheiro S; de Paiva Neto MA
    J Neurooncol; 2018 Apr; 137(2):331-336. PubMed ID: 29270884
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and histopathological predictors of outcome in malignant meningioma.
    Maier AD; Bartek J; Eriksson F; Ugleholdt H; Juhler M; Broholm H; Mathiesen TI
    Neurosurg Rev; 2020 Apr; 43(2):643-653. PubMed ID: 30868425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Microvascularization of Grade I meningiomas: effect on tumor volume, blood loss, and patient outcome.
    Karsy M; Burnett B; Di Ieva A; Cusimano MD; Jensen RL
    J Neurosurg; 2018 Mar; 128(3):657-666. PubMed ID: 28362240
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Re-irradiation for recurrent intracranial meningiomas: Analysis of clinical outcomes and prognostic factors.
    Desideri I; Morelli I; Banini M; Greto D; Visani L; Nozzoli F; Caini S; Della Puppa A; Livi L; Perini Z; Zivelonghi E; Bulgarelli G; Pinzi V; Navarria P; Clerici E; Scorsetti M; Ascolese AM; Osti MF; Anselmo P; Amelio D; Minniti G; Scartoni D
    Radiother Oncol; 2024 Jun; 195():110271. PubMed ID: 38588920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis.
    Sahm F; Schrimpf D; Stichel D; Jones DTW; Hielscher T; Schefzyk S; Okonechnikov K; Koelsche C; Reuss DE; Capper D; Sturm D; Wirsching HG; Berghoff AS; Baumgarten P; Kratz A; Huang K; Wefers AK; Hovestadt V; Sill M; Ellis HP; Kurian KM; Okuducu AF; Jungk C; Drueschler K; Schick M; Bewerunge-Hudler M; Mawrin C; Seiz-Rosenhagen M; Ketter R; Simon M; Westphal M; Lamszus K; Becker A; Koch A; Schittenhelm J; Rushing EJ; Collins VP; Brehmer S; Chavez L; Platten M; Hänggi D; Unterberg A; Paulus W; Wick W; Pfister SM; Mittelbronn M; Preusser M; Herold-Mende C; Weller M; von Deimling A
    Lancet Oncol; 2017 May; 18(5):682-694. PubMed ID: 28314689
    [TBL] [Abstract][Full Text] [Related]  

  • 13. TERT Promoter Mutations and Risk of Recurrence in Meningioma.
    Sahm F; Schrimpf D; Olar A; Koelsche C; Reuss D; Bissel J; Kratz A; Capper D; Schefzyk S; Hielscher T; Wang Q; Sulman EP; Adeberg S; Koch A; Okuducu AF; Brehmer S; Schittenhelm J; Becker A; Brokinkel B; Schmidt M; Ull T; Gousias K; Kessler AF; Lamszus K; Debus J; Mawrin C; Kim YJ; Simon M; Ketter R; Paulus W; Aldape KD; Herold-Mende C; von Deimling A
    J Natl Cancer Inst; 2016 May; 108(5):. PubMed ID: 26668184
    [TBL] [Abstract][Full Text] [Related]  

  • 14. World Health Organization Grade III (Nonanaplastic) Meningioma: Experience in a Series of 23 Cases.
    Zhang GJ; Zhang GB; Zhang YS; Li H; Li CB; Zhang LW; Li D; Wu Z; Zhang JT
    World Neurosurg; 2018 Apr; 112():e754-e762. PubMed ID: 29382616
    [TBL] [Abstract][Full Text] [Related]  

  • 15. De novo and secondary anaplastic meningiomas: a study of clinical and histomolecular prognostic factors.
    Peyre M; Gauchotte G; Giry M; Froehlich S; Pallud J; Graillon T; Bielle F; Cazals-Hatem D; Varlet P; Figarella-Branger D; Loiseau H; Kalamarides M
    Neuro Oncol; 2018 Jul; 20(8):1113-1121. PubMed ID: 29216385
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stereotactic radiosurgery of World Health Organization grade II and III intracranial meningiomas: treatment results on the basis of a 22-year experience.
    Pollock BE; Stafford SL; Link MJ; Garces YI; Foote RL
    Cancer; 2012 Feb; 118(4):1048-54. PubMed ID: 21773968
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The clinicopathological analysis of receptor tyrosine kinases in meningiomas: the expression of VEGFR-2 in meningioma was associated with a higher WHO grade and shorter progression-free survival.
    Nakada S; Sasagawa Y; Tachibana O; Iizuka H; Kurose N; Shioya A; Guo X; Yamada S; Nojima T
    Brain Tumor Pathol; 2019 Jan; 36(1):7-13. PubMed ID: 30519894
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pathodiagnostic parameters and evaluation of O⁶- methyl guanine methyl transferase gene promoter methylation in meningiomas.
    Jabini R; Moradi A; Afsharnezhad S; Ayatollahi H; Behravan J; Raziee HR; Mosaffa F
    Gene; 2014 Apr; 538(2):348-53. PubMed ID: 24398011
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Survival impacts of extent of resection and adjuvant radiotherapy for the modern management of high-grade meningiomas.
    Li D; Jiang P; Xu S; Li C; Xi S; Zhang J; Chen Y; Jiang X; Zhang X; Sai K; Wang J; Mou Y; Ke C; Chen Z
    J Neurooncol; 2019 Oct; 145(1):125-134. PubMed ID: 31493161
    [TBL] [Abstract][Full Text] [Related]  

  • 20. TERT promoter mutations in primary and secondary WHO grade III meningioma.
    Maier AD; Stenman A; Svahn F; Mirian C; Bartek J; Juhler M; Zedenius J; Broholm H; Mathiesen T
    Brain Pathol; 2021 Jan; 31(1):61-69. PubMed ID: 32805769
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.